Progyny, Inc. (PGNY) — ESG & Values Scores

Environment story

Progyny has not disclosed Scope 1, 2, or 3 emissions data, net-zero targets, or environmental initiatives in the 10-K filing. The company operates a fertility benefits platform with no direct manufacturing or significant resource extraction operations, minimizing direct environmental impact. However, the absence of any climate commitments, emissions disclosures, or sustainability targets results in substantial deductions. No environmental controversies or regulatory proceedings are documented. The company's use of AI and cloud infrastructure may entail upstream Scope 3 emissions from data centers, but these are not quantified or addressed.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

No disclosed initiatives on file for this pillar.

Social story

Progyny demonstrates moderate social performance. The company employs a workforce comprising Progyny Care Advocates (PCAs), clinical support staff, and corporate personnel. No CEO-to-median-worker pay ratio or workforce diversity metrics are disclosed in the 10-K. No documented union-suppression activities, major strikes, or labor disputes are reported within the last 24 months. The company acquired Benefit Bump LLC (parental leave navigation) and Apryl GmbH (fertility benefits platform), expanding family-building offerings. No supply-chain human-rights controversies (e.g., cobalt mining) are evident given the company's service-based business model. Turnover rates, detailed diversity breakdowns, and union standing are undisclosed. The company does not appear to conduct animal testing.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Parental Leave Benefits Navigation

Acquired Benefit Bump LLC in January 2025 to provide comprehensive parental leave benefits navigation for new and growing families.

Expands family-building solution portfolio and enhances employee benefits for family planning.
Women's Health Expansion

Expanded offerings to include pregnancy and postpartum, menopause and midlife care, benefit and leave navigation, and parent and child wellbeing solutions.

Broadens coverage of reproductive and women's health benefits for covered members.

Governance story

Progyny operates under a single-class share structure (no disclosed dual-class voting rights), supporting governance equity. Board independence percentage is not disclosed in the 10-K. The company does not appear to engage in active lobbying to weaken climate or consumer-protection regulation based on available filings. No active antitrust, consumer-safety, or financial-fraud regulatory proceedings are documented. The company maintains a $200 million revolving credit facility (established July 1, 2025) and has implemented share repurchase programs ($300+ million in total repurchases through 2025). Cybersecurity and data privacy risks are extensively documented as material risks given the company's handling of protected health information (PHI) under HIPAA. No shareholder lawsuits blocking climate proposals or major governance violations are evident.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Cybersecurity and Data Privacy Compliance

Company maintains cyber liability insurance and implements security measures to comply with HIPAA privacy and security standards. OCR (Office for Civil Rights) enforcement and Business Associate compliance are ongoing priorities.

Mitigates risk of data breaches and regulatory penalties under HIPAA; supports member and client trust.
Revolving Credit Facility

Entered into $200 million revolving credit facility (JPMorgan Chase) maturing July 1, 2030, with compliance with all financial covenants as of December 31, 2025.

Strengthens liquidity and financial flexibility for operations and strategic investments.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Progyny, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Progyny, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)